"SAGA Diagnostics AB...has entered into an assay development agreement with the global, science-led biopharmaceutical company AstraZeneca...SAGA Diagnostics will in the course of this agreement develop unique SAGAsafe® dPCR assays towards undisclosed methylated targets for analyses of tissue samples and liquid biopsies."
"SAGA Diagnostics AB...adapted a SAGAsafe® PIK3CA 24-plex mutation detection assay to work on Stilla Technologies’ new naica® Prism 6 system which was presented at this year’s Annual Meeting of the American Society of Human Genetics (ASHG) on October 14."